Correlation of retinal vascular characteristics with laboratory and ocular findings in Fabry disease: exploring ocular diagnostic biomarkers.
Biomarkers
Fabry disease
OCT angiography
Vascular remodelling
Vessel area density
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
08 10 2023
08 10 2023
Historique:
received:
08
11
2022
accepted:
25
09
2023
medline:
10
10
2023
pubmed:
9
10
2023
entrez:
8
10
2023
Statut:
epublish
Résumé
The goal of this study was to evaluate macular microvascular changes in patients with Fabry disease (FD) using optical coherence tomography angiography (OCTA) and to explore their correlation with laboratory and ocular findings. A total of 76 eyes (38 patients) and 48 eyes of 24 healthy controls were enrolled in this prospective study. Vessel Area Density (VAD) and Foveal Avascular Zone (FAZ) area were calculated on 2.9 × 2.9 mm OCTA images scanned with the Heidelberg Spectralis II (Heidelberg, Germany). VAD was measured in three layers: Superficial Vascular Plexus (SVP), Intermediate Capillary Plexus (ICP), and Deep Capillary Plexus (DCP). All scans were analyzed with the EA-Tool (Version 1.0), which was coded in MATLAB (The MathWorks Inc, R2017b). FAZ area was manually measured in full-thickness, SVP, ICP and DCP scans. Average VAD in SVP, ICP and DCP was higher in Fabry disease patients than in controls (49.4 ± 11.0 vs. 26.5 ± 6.2, 29.6 ± 7.4 vs. 20.2 ± 4.4, 32.3 ± 8.8 vs. 21.7 ± 5.1 respectively, p < 0.001). Patients with cornea verticillata (CV) had a higher VAD in ICP and DCP compared to patients without CV (p < 0.01). Patients with increased lysoGb3 concentration had a higher VAD in DCP when compared to patients with normal lysoGb3 concentration (p < 0.04). There was no difference in VAD in patients with and without vascular tortuosity. However, a significantly higher VAD was observed in patients with vascular tortuosity compared to controls (p < 0.03). Increased lysoGb3 and VAD in DCP could be reliable biomarkers of disease activity. Cornea verticillata could be adopted as a predictive biomarker for VAD changes and disease progression. The combination of cornea verticillata and increased VAD may serve as a diagnostic biomarker for Fabry disease, however due to the discrepancies in VAD values in various studies, further research has to be done to address this claim.
Sections du résumé
BACKGROUND
The goal of this study was to evaluate macular microvascular changes in patients with Fabry disease (FD) using optical coherence tomography angiography (OCTA) and to explore their correlation with laboratory and ocular findings.
METHODS
A total of 76 eyes (38 patients) and 48 eyes of 24 healthy controls were enrolled in this prospective study. Vessel Area Density (VAD) and Foveal Avascular Zone (FAZ) area were calculated on 2.9 × 2.9 mm OCTA images scanned with the Heidelberg Spectralis II (Heidelberg, Germany). VAD was measured in three layers: Superficial Vascular Plexus (SVP), Intermediate Capillary Plexus (ICP), and Deep Capillary Plexus (DCP). All scans were analyzed with the EA-Tool (Version 1.0), which was coded in MATLAB (The MathWorks Inc, R2017b). FAZ area was manually measured in full-thickness, SVP, ICP and DCP scans.
RESULTS
Average VAD in SVP, ICP and DCP was higher in Fabry disease patients than in controls (49.4 ± 11.0 vs. 26.5 ± 6.2, 29.6 ± 7.4 vs. 20.2 ± 4.4, 32.3 ± 8.8 vs. 21.7 ± 5.1 respectively, p < 0.001). Patients with cornea verticillata (CV) had a higher VAD in ICP and DCP compared to patients without CV (p < 0.01). Patients with increased lysoGb3 concentration had a higher VAD in DCP when compared to patients with normal lysoGb3 concentration (p < 0.04). There was no difference in VAD in patients with and without vascular tortuosity. However, a significantly higher VAD was observed in patients with vascular tortuosity compared to controls (p < 0.03).
CONCLUSIONS
Increased lysoGb3 and VAD in DCP could be reliable biomarkers of disease activity. Cornea verticillata could be adopted as a predictive biomarker for VAD changes and disease progression. The combination of cornea verticillata and increased VAD may serve as a diagnostic biomarker for Fabry disease, however due to the discrepancies in VAD values in various studies, further research has to be done to address this claim.
Identifiants
pubmed: 37807078
doi: 10.1186/s13023-023-02932-x
pii: 10.1186/s13023-023-02932-x
pmc: PMC10561444
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
314Informations de copyright
© 2023. Institut National de la Santé et de la Recherche Médicale (INSERM).
Références
Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):2812-7
pubmed: 18287059
Lasers Med Sci. 2022 Feb;37(1):269-277
pubmed: 33409749
PLoS One. 2017 Nov 27;12(11):e0188572
pubmed: 29176837
Elife. 2018 Mar 21;7:
pubmed: 29561727
Eur J Ophthalmol. 2021 Nov;31(6):3231-3237
pubmed: 33225739
J Hum Hypertens. 2007 Jan;21(1):20-7
pubmed: 17096009
Sci Rep. 2017 Feb 10;7:42201
pubmed: 28186181
J Pak Med Assoc. 2014 Feb;64(2):189-94
pubmed: 24640811
Br J Ophthalmol. 2007 Feb;91(2):210-4
pubmed: 16973664
Cureus. 2020 Dec 14;12(12):e12083
pubmed: 33489501
Am J Med Sci. 2020 Dec;360(6):641-649
pubmed: 32723516
Ophthalmologica. 2020;243(1):75-84
pubmed: 31509842
J Neurol Sci. 2014 Sep 15;344(1-2):5-19
pubmed: 25106696
Ophthalmol Ther. 2023 Oct;12(5):2713-2727
pubmed: 37542614
Biochem Pharmacol. 2009 Sep 15;78(6):539-52
pubmed: 19413999
Light Sci Appl. 2022 Mar 18;11(1):63
pubmed: 35304441
Front Neurol. 2021 Mar 09;12:640719
pubmed: 33767663
Int Ophthalmol. 2020 Nov;40(11):3023-3032
pubmed: 32607948
Clin Exp Ophthalmol. 2005 Apr;33(2):164-8
pubmed: 15807825
J Clin Med. 2019 Apr 17;8(4):
pubmed: 30999633
Orphanet J Rare Dis. 2021 Nov 20;16(1):485
pubmed: 34801073
J Clin Med. 2021 Mar 05;10(5):
pubmed: 33807900
Arterioscler Thromb Vasc Biol. 2008 May;28(5):812-9
pubmed: 18276911
Handb Clin Neurol. 2015;132:231-48
pubmed: 26564084
Mol Genet Metab. 2010 Feb;99(2):99-108
pubmed: 19900828
Invest Ophthalmol Vis Sci. 2019 Jun 3;60(7):2667-2675
pubmed: 31242288
Mol Genet Metab. 2018 Apr;123(4):416-427
pubmed: 29530533
Cureus. 2022 Aug 4;14(8):e27669
pubmed: 36072178
J Neurol Sci. 2007 Jun 15;257(1-2):258-63
pubmed: 17362993
Mol Genet Metab. 2010 Jul;100(3):257-61
pubmed: 20409739
Int J Mol Sci. 2020 Oct 29;21(21):
pubmed: 33138098